Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
|Articles|October 28, 2022
- October 2022
- Volume 88
- Issue 10
October Pet Peeves
Advertisement
Missed Call
When the pharmacy calls a patient and leaves a voicemail message about a prescription, and the patient calls back and says they did not listen to the message and asks what the call was about.
Getting Carded
Patients who show up to get COVID-19 boosters and leave their CDC cards at home. They get reminders to have the cards but still say, “Oh, I didn’t know I’d need to bring that.”
Positively Dreadful
Patients who test positive for COVID-19 and then arrive without a mask on to pick up their Rx.
Articles in this issue
about 4 years ago
October Fun Factsabout 4 years ago
Investigators Suggest Conjunctivitis May Transmit Monkeypoxabout 4 years ago
Women Pharmacist Day Focuses on Achievements in the Professionabout 4 years ago
October Generic Product Newsabout 4 years ago
Pharmacists Play Pivotal Role in Increasing Awareness of Prediabetesabout 4 years ago
October Generic Focusabout 4 years ago
Federal ECHO Act Helps Goal of Health Equityabout 4 years ago
October Rx Product NewsAdvertisement
Related to this article
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
If gene therapies are expected to deliver decades of benefit, long-term evidence collection must be coordinated, useful to patients, and financially sustainable.
As kratom questions increase, many pharmacists and other health care professionals may remain unfamiliar it and the potential risks.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Accelerated approval for patients who progressed on platinum and immunotherapy brings a new mechanism—and a familiar toxicity profile.
If approved, the combination would be the first chemotherapy-free, Bruton tyrosine kinase inhibitor–based regimen for adults with newly diagnosed mantle cell lymphoma (MCL).
Advertisement
Advertisement
Trending on Pharmacy Times
1
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
2
FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL
3
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
4
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
5